This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kemp, T. J.
Right arrow Articles by Pinto, L. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kemp, T. J.
Right arrow Articles by Pinto, L. A.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, January 2008, p. 60-64, Vol. 15, No. 1
1071-412X/08/$08.00+0     doi:10.1128/CVI.00118-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Evaluation of Two Types of Sponges Used To Collect Cervical Secretions and Assessment of Antibody Extraction Protocols for Recovery of Neutralizing Anti-Human Papillomavirus Type 16 Antibodies{triangledown}

Troy J. Kemp,1 Allan Hildesheim,2 Roni T. Falk,2 John T. Schiller,3 Douglas R. Lowy,3 Ana Cecilia Rodriguez,4 and Ligia A. Pinto1*

HPV Immunology Laboratory, SAIC-Frederick, Inc., NCI-Frederick, Frederick, Maryland,1 Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland,2 Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland,3 Proyecto Epidemiológico Guanacaste, San José, Costa Rica4

Received 13 March 2007/ Returned for modification 17 June 2007/ Accepted 3 November 2007

Immunogenicity evaluations in human papillomavirus (HPV) vaccine trials have relied on serological samples, yet cervical antibodies are likely to be most relevant for protection against infection. In order to assess functional antibody levels at the cervix, the secreted-alkaline-phosphatase neutralization assay (SEAPNA) was used to measure HPV-neutralizing activity. We assessed the variability of the SEAPNA with serum samples after vaccination with an HPV type 16 (HPV16) L1 virus-like particle vaccine and whether the SEAPNA can be used to monitor neutralizing activity at the cervix. The SEAPNA has an overall coefficient of variation of 29.3%. Recovery from ophthalmic sponges was assessed by spiking V5 (mouse anti-HPV16) antibody onto and extracting it from sterile Merocel and Ultracell sponges and sponges used to collect specimens from participants. V5 recovery from sterile Merocel sponges was complete, yet that from Ultracell sponges was null. The mean V5 recoveries from participant Ultracell and Merocel sponges were 61.2% and 93.5%, respectively, suggesting that Merocel sponges are more appropriate for specimen collection. The SEAPNA can be applied to determine the surrogates of protection and to examine the durability of protection at the cervix.

* Corresponding author. Mailing address: HPV Immunology Laboratory, NCI-Frederick/SAIC-Frederick, Inc., Building 469, Room 120, Frederick, MD 21702. Phone: (301) 846-1766. Fax: (301) 846-6954. E-mail: lpinto{at}ncifcrf.gov

{triangledown} Published ahead of print on 21 November 2007.

Clinical and Vaccine Immunology, January 2008, p. 60-64, Vol. 15, No. 1
1071-412X/08/$08.00+0     doi:10.1128/CVI.00118-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»